study_id,year,design,effect_type,effect_point,ci_low,ci_high,n_treat,n_ctrl,risk_of_bias,doi,journal_id,outcome,population,adverse_events,duration_weeks
INFL-INF13-01,2014,randomized controlled trial,SMD,-0.3104,-0.4921,-0.1287,92,92,some concerns,10.1234/infl-inf13-01,inflammation-journal-01,recovery,Adults with recovery concerns,Transient headache,9
INFL-INF13-02,2019,randomized controlled trial,SMD,-0.305,-0.4691,-0.1409,75,77,mixed,10.1234/infl-inf13-02,inflammation-journal-02,recovery,Adults with recovery concerns,Mild GI discomfort,13
INFL-INF13-03,2010,randomized controlled trial,SMD,-0.2996,-0.4462,-0.153,88,92,low,10.1234/infl-inf13-03,inflammation-journal-03,recovery,Adults with recovery concerns,None reported,12
